Skip to main content
SpringerLink
Log in

Osteoporosis in Ankylosing Spondylitis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Osteoporosis (OP) is a frequent complication of ankylosing spondylitis (AS), even in early stages of the disease, and is associated with elevated levels of biochemical markers of bone turnover, proinflammatory cytokines, and acute-phase reactants. This suggests that systemic inflammatory mediators, such as interleukin-6 and tumor necrosis factor-α, may be involved. Various factors that conceivably work in conjunction with one another also cause bone loss in AS (eg, genetic polymorphisms of vitamin D, low levels of osteoprotegerin and sex steroid hormones, and impaired calcium and vitamin D absorption). Dual x-ray absorptiometry for assessing bone mineral density (BMD) has limitations in patients with AS because of unreliability of spinal measurements, particularly in advanced disease with new bone formation. Femoral neck BMD is reduced and correlates with increased risk of vertebral fractures. Hence, measurement of BMD at the femoral neck may provide the most accurate means of detecting osteopenia and OP and could assess fracture risk in AS patients. No guidelines are available for detection and treatment of OP in AS, and most patients are young men, who are less likely to be screened. The only evidence-based recommendation is that optimal control of disease activity in AS prevents bone loss. A recent study showed a beneficial effect of infliximab therapy on bone turnover markers and BMD in AS. Also, bisphosphonates may be useful in managing OP in AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Calin A: Osteoporosis and ankylosing spondylitis. Br J Rheumatol 1991, 30:318–319.

    Google Scholar 

  2. Reid DM, Nicoll JJ, Kennedy NS, et al.: Bone mass in ankylosing spondylitis. J Rheumatol 1986, 13:932–935.

    CAS  PubMed  Google Scholar 

  3. El Maghraoui A: Osteoporosis and ankylosing spondylitis. Jt Bone Spine, 2004, 71:291–295.

    Article  Google Scholar 

  4. Baek HJ, Kang SW, Lee YJ, et al.: Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005, 26:30–34.

    Article  CAS  PubMed  Google Scholar 

  5. • Ghozlani I, Ghazi M, Nouijai A, et al.: Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009, 44:772–776. This study calculated the prevalence and risk factors of OP and vertebral fractures in patients with AS.

    Article  CAS  PubMed  Google Scholar 

  6. Vosse D, Landewé R, van der Heijde D, et al.: Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case control study. Ann Rheum Dis 2009, 68:1839–1842.

    Article  CAS  PubMed  Google Scholar 

  7. Geusens P, Vosse D, van der Linden S: Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007, 19:335–339.

    Article  PubMed  Google Scholar 

  8. Ralston SH, Urquhart GD, Brzeski M, Sturrock RD: Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990, 300:563–565.

    Article  CAS  PubMed  Google Scholar 

  9. Donnelly S, Doyle DV, Denton A, et al.: Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994, 53:117–121.

    Article  CAS  PubMed  Google Scholar 

  10. Cooper C, Carbone L, Michet CJ, et al.: Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994, 21:1877–1882.

    CAS  PubMed  Google Scholar 

  11. El Maghraoui A, Borderie D, Cherruau B, et al.: Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999, 26:2205–2209.

    CAS  PubMed  Google Scholar 

  12. Hanson CA, Shagrin JW, Duncan H: Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res 1971, 74:59–64.

    Article  CAS  PubMed  Google Scholar 

  13. Mitra D, Elvins DM, Speden DJ, Collins AJ: The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 2000, 39:85–89.

    Article  CAS  Google Scholar 

  14. Gratacos J, Collado A, Pons F, et al.: Significant bone mass in patients with early, active ankylosing spondylitis. Arthritis Rheum 1999, 42:2319–2324.

    Article  CAS  PubMed  Google Scholar 

  15. Maillefert JF, Aho LS, El Maghraoui A, et al.: Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001, 12:605–609.

    Article  CAS  PubMed  Google Scholar 

  16. Franck H, Meurer T, Hofbauer LC: Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004, 31:2236–2241.

    CAS  PubMed  Google Scholar 

  17. Wendling D: Bone loss in ankylosing spondylitis: can we put the puzzle together? J Rheumatol 2005, 32:1184–1185.

    PubMed  Google Scholar 

  18. Walsh NC, Gravallese M: Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 2004, 16:419–427.

    Article  PubMed  Google Scholar 

  19. Lubberts E, Van Der Bersselaar L, Oppers-Walgreen B, et al.: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170:2655–2662.

    CAS  PubMed  Google Scholar 

  20. Obermayer-Pietsch BM, Lange U, Tauber G, et al.: Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 2003, 14:995–1000.

    Article  CAS  PubMed  Google Scholar 

  21. Karberg K, Zochling J, Sieper J, et al.: Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005, 32:1290–1298.

    PubMed  Google Scholar 

  22. Lodder MC, de Jong Z, Kostense PJ, et al.: Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004, 63:1576–1580.

    Article  CAS  PubMed  Google Scholar 

  23. Devogelaer JP, Maldague B, Malghem J, et al.: Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992, 35:1062–1067.

    Article  CAS  PubMed  Google Scholar 

  24. Capaci K, Hepguler S, Argin M, Tas I: Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 2003, 44:379–384.

    PubMed  Google Scholar 

  25. Jun JB, Joo KB, Her MY, et al.: Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 2006, 33:1637–1641.

    PubMed  Google Scholar 

  26. Lange U, Kluge A, Strunk J, et al.: Ankylosing spondylitis and bone mineral density—what is the ideal tool for measurement? Rheumatol Int 2005, 26:115–120.

    Article  PubMed  Google Scholar 

  27. Toussirot E, Michel F, Wendling D: Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 2001, 40:882–888.

    Article  CAS  PubMed  Google Scholar 

  28. Speden DJ, Calin AI, Ring FJ, Bhalla AK: Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002, 29:516–521.

    PubMed  Google Scholar 

  29. Yilmaz N, Ozaslan J: Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000, 19:92–98.

    Article  CAS  PubMed  Google Scholar 

  30. Toussirot E, Ricard-Blum S, Dumoulin G, et al.: Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 1999, 38:21–27.

    Article  CAS  Google Scholar 

  31. Grisar J, Bernecker PM, Aringer M, et al.: Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002, 29:1430–1436.

    PubMed  Google Scholar 

  32. Bessant R, Harris C, Keat A: Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol 2003, 30:779–782.

    PubMed  Google Scholar 

  33. Bessant R, Keat A: How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 2002, 29:1511–1519.

    PubMed  Google Scholar 

  34. Barnabe C, Hanley DA: Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009, 39:116–122.

    Article  CAS  PubMed  Google Scholar 

  35. Allali F, Breban M, Porcher R, et al.: Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor. Ann Rheum Dis 2003, 62:347–349.

    Article  CAS  PubMed  Google Scholar 

  36. Demis E, Roux C, Breban M, Dougados M: Infliximab in spondyloarthropathy—influence on bone density. Clin Exp Rheumatol 2002, 20(6 Suppl 28):S185–S186.

    CAS  PubMed  Google Scholar 

  37. •• Visvanathan S, van der Heijde D, Deodhar A, et al.: Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175–182. This was a placebo-controlled, randomized study with infliximab in AS. Patients with AS who received infliximab showed significant increases in BMD scores over 2 years.

    Article  CAS  PubMed  Google Scholar 

  38. Toussirot E, Wendling D: Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007, 19:340–345.

    Article  CAS  PubMed  Google Scholar 

  39. Cairns AP, Wright SA, Taggart AJ, et al.: An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover [letter]. Ann Rheum Dis 2005, 64:338–339.

    Article  CAS  PubMed  Google Scholar 

  40. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766–773.

    Article  CAS  PubMed  Google Scholar 

  41. • Sidiropoulos PI, Hatemi G, Song IH, et al.: Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008, 47:355–361. This article includes evidence-based recommendations for management of AS. It is a part of the 3E Initiative in Rheumatology, a multinational effort to develop recommendations for the management of rheumatic diseases that involves a large number of experts combined with practicing rheumatologists addressing specific questions relevant to clinical practice.

    Article  CAS  Google Scholar 

  42. • Kanis JA, Johnell O, Oden A, et al.: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385–397. In this study, models were applied for the prediction of fractures in men and women using clinical risk factors for fracture with and without the use of femoral neck BMD. Four models were constructed to compute fracture probabilities based on the epidemiology of fracture in the United Kingdom. The models provide a framework that enhances the assessment of fracture risk in men and women via the integration of clinical risk factors alone and/or in combination with BMD.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Rheumatology, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH, 44109, USA

    Marina Magrey & Muhammad Asim Khan

Authors
  1. Marina Magrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Asim Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Magrey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magrey, M., Khan, M.A. Osteoporosis in Ankylosing Spondylitis. Curr Rheumatol Rep 12, 332–336 (2010). https://doi.org/10.1007/s11926-010-0122-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0122-1

Keywords

Search

Navigation